3 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text

Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

Journal of the American Academy of Dermatology
Volume 58, n° 3
pages 480-484 (mars 2008)
Doi : 10.1016/j.jaad.2007.12.012
Case Reports

CD4+ CD56+ hematodermic/plasmacytoid dendritic cell tumor with response to pralatrexate

Justin J. Leitenberger, BS a, Cindy N. Berthelot, MD a, , Kristel D. Polder, MD a, Barbara Pro, MD b, Peter McLaughlin, MD b, Dan Jones, MD, PhD c, Madeleine Duvic, MD a
a Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas 
b Department of Lymphoma, The University of Texas MD Anderson Cancer Center, Houston, Texas 
c Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas 

Reprint requests: Cindy N. Berthelot, MD, Department of Dermatology, The University of Texas, MD Anderson Cancer Center, 1515 Holcombe Blvd, Box 434, Houston, Texas 77030-4009.

The CD4+ CD56+ hematodermic/plasmacytoid dendritic cell tumor is a rare, highly aggressive, systemic neoplasm for which effective therapies have not yet been established. These tumors express CD4, CD56, CD123, and T-cell leukemia/lymphoma (TCL)-1 and are clinically characterized by cutaneous involvement with spread to bone marrow and blood, and poor prognosis with current chemotherapy regimens. We describe a Caucasian woman who presented with plasmacytoid dendritic cell tumor, but an absence of systemic symptoms. Clinically, multiple cutaneous lesions were brown to violaceous firm nodules on the face, arms, and trunk. The patient underwent two courses of cyclophosphamide, Adriamycin, vincristine, and prednisone chemotherapy but relapsed quickly. The investigational agent, pralatrexate (30 mg/m2) was given weekly with vitamin B12 and folic acid and resulted in remarkable clinical response with regression of skin tumors. Our observation highlights pralatrexate as a promising therapeutic option for hematodermic/plasmacytoid dendritic cell lymphoma/leukemias.

The full text of this article is available in PDF format.

Abbreviations used : CHOP, pDC, NK, TCL

 Supported in part by Sherry L. Anderson Cutaneous T-cell Lymphoma Research Fund, National Institutes of Health Grant K24-CA86815, and MD Anderson Core Grant CA16672.
 Conflicts of interest: None declared.

© 2008  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Article Outline
You can move this window by clicking on the headline